BCR and ovarian benign neoplasm: Given its role as the most variable TCR clonotype and a key determinant of antigen binding, the CDR3 region was investigated to assess the clonal heterogeneity of TCR β-chain and BCR H-chain repertoires in patients with malignant and benign ovarian tumors.